Published in Cancer Commun on July 01, 1991
The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev (1993) 1.59
Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer (1997) 1.32
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer (1994) 1.00
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer (1995) 0.95
Enzymology of bioreductive drug activation. Br J Cancer Suppl (1996) 0.94
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer (1995) 0.93
High throughput screening for inhibitors of alpha-galactosidase. Curr Chem Genomics (2010) 0.92
The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release. Org Lett (2010) 0.91
Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol (2008) 0.88
Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Br J Cancer (1997) 0.88
Mouse liver NAD(P)H:quinone acceptor oxidoreductase: protein sequence analysis by tandem mass spectrometry, cDNA cloning, expression in Escherichia coli, and enzyme activity analysis. Protein Sci (1994) 0.87
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer (2004) 0.86
A two-domain structure for the two subunits of NAD(P)H:quinone acceptor oxidoreductase. Protein Sci (1994) 0.85
EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol (2013) 0.85
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer (2001) 0.83
Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer (1995) 0.81
Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol (2002) 0.81
Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol (1996) 0.80
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol (2009) 0.79
Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br J Cancer (1997) 0.78
The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone. Breast Cancer Res (2004) 0.75
Azoreductases in drug metabolism. Br J Pharmacol (2016) 0.75
Influence of bulk and tapped density on the determination of the thermal conductivity of powders and blends. AAPS PharmSciTech (2007) 0.75
Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ (1992) 7.20
A venue-based method for sampling hard-to-reach populations. Public Health Rep (2001) 6.43
Identification and characterization of the STIM (stromal interaction molecule) gene family: coding for a novel class of transmembrane proteins. Biochem J (2001) 3.77
STIM1: a novel phosphoprotein located at the cell surface. Biochim Biophys Acta (2000) 3.67
Structural details of double-helix observed for DNAs containing alternating purine and pyrimidine sequences. J Mol Biol (1974) 3.33
Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature (1993) 3.24
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care (1995) 2.99
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Plasma membrane Ca2+-ATPase extrudes Ca2+ from hair cell stereocilia. J Neurosci (1998) 2.14
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Models of triple-stranded polynucleotides with optimised stereochemistry. Nucleic Acids Res (1976) 2.06
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother (2007) 1.93
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
A prospective comparative study of the AMO ARRAY zonal-progressive multifocal silicone intraocular lens and a monofocal intraocular lens. Ophthalmology (1999) 1.84
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
Molecular cloning of a novel human gene (D11S4896E) at chromosomal region 11p15.5. Genomics (1996) 1.80
A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry (1987) 1.79
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis (1998) 1.77
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Role for the plasmodium falciparum digestive vacuole in chloroquine resistance. Biochem Pharmacol (1998) 1.65
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population. Pediatrics (1997) 1.63
Silicone arthroplasty for trapeziometacarpal arthritis. J Hand Surg Br (2002) 1.63
The relationship between height velocity and growth hormone secretion in short prepubertal children. Clin Endocrinol (Oxf) (1987) 1.61
Birefringence imaging directly reveals architectural dynamics of filamentous actin in living growth cones. Mol Biol Cell (1999) 1.61
Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med (1998) 1.61
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Continuous intercostal nerve block for pain relief after thoracotomy. Ann Thorac Surg (1988) 1.58
Acidification of the male reproductive tract by a proton pumping (H+)-ATPase. Nat Med (1996) 1.55
The effects of steel and titanium mandibular reconstruction plates on photon and electron beams. Br J Radiol (1990) 1.53
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Lichen sclerosus et atrophicus. A common and distinctive cause of phimosis in boys. Arch Dermatol (1984) 1.50
Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms' tumours. Oncogene (1992) 1.50
Value of factor VIII related antigen as a means of demonstrating extramedullary megakaryopoiesis. J Clin Pathol (1984) 1.49
Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin's lymphomas. J Pathol (1988) 1.49
Survey of physician practice behaviors related to diabetes mellitus in the U.S. Physician adherence to consensus recommendations. Diabetes Care (1993) 1.47
A community-level HIV prevention intervention for inner-city women: results of the women and infants demonstration projects. Am J Public Health (2000) 1.46
Prostatectomy in the over 80-year-old. Br J Urol (1989) 1.46
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) (2003) 1.43
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
"Should we treat leuchaemia in children?". Med J Aust (2001) 1.40
Bladder irrigation with chlorhexidine for the prevention of urinary infection after transurethral operations: a prospective controlled study. J Urol (1987) 1.39
Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour. Eur J Cancer (1995) 1.39
Hyaluronic acid: structure of a fully extended 3-fold helical sodium salt and comparison with the less extended 4-fold helical forms. J Mol Biol (1975) 1.39
Anomalous extensor muscles of the hand: a review. J Hand Surg Am (1999) 1.38
Care of the acutely injured hand. Br Med J (Clin Res Ed) (1985) 1.37
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
Hyaluronic acid: molecular conformations and interactions in two sodium salts. J Mol Biol (1975) 1.29
The epidemiology of diabetes and pregnancy in the U.S., 1988. Diabetes Care (1995) 1.28
The use of Sternberg's memory-scanning paradigm in assessing effects of chemical exposure. Hum Factors (1981) 1.28
Comparison between a physiological and a pharmacological stimulus of growth hormone secretion: response to stage IV sleep and insulin-induced hypoglycaemia. Lancet (1985) 1.27
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci U S A (1992) 1.26
Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J Speech Lang Hear Res (2001) 1.26
Ataxia telangiectasia: an inherited human disorder involving hypersensitivity to ionizing radiation and related DNA-damaging chemicals. Annu Rev Genet (1979) 1.25
Immunohistochemical localisation of factor VIII-related antigen in Hodgkin's disease. J Clin Pathol (1984) 1.25
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene (2008) 1.24
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol (2001) 1.24
Oxygen-depleted zones inside reproductive structures of Brassicaceae: implications for oxygen control of seed development. Can J Bot (1999) 1.24
Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer (1992) 1.24
Liver disease in patients with joint symptoms. Ann Rheum Dis (1974) 1.23
A quantitative study of mast cells in Hodgkin's disease. J Clin Pathol (1984) 1.23
Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol (1999) 1.23
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer (1979) 1.23
The anatomical basis of the groin flap. Plast Reconstr Surg (1972) 1.22
Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res (1995) 1.22
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Flow cytometric fluorescence emission spectrum analysis of Hoechst-33342-stained DNA in chicken thymocytes. Cytometry (1985) 1.21
A third Wilms' tumor locus on chromosome 16q. Cancer Res (1992) 1.20
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer (1999) 1.17
TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res (1996) 1.17
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 1.16
Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet (1991) 1.16
Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care (1995) 1.16
Herd fertility and Corynebacterium haemolyticum in bovine semen. Vet Rec (1968) 1.16
The self-referencing oxygen-selective microelectrode: detection of transmembrane oxygen flux from single cells. J Exp Biol (1999) 1.15
Vaccination status of children in the Women, Infants, and Children (WIC) Program: are we doing enough to improve coverage? Am J Prev Med (2001) 1.15
Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol (1981) 1.14
The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg (2000) 1.14
Microbiology of the urethral (frequency and dysuria) syndrome. A controlled study with 5-year review. Br J Urol (1989) 1.13
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
Effect of occupational exposure to elemental mercury on short term memory. Br J Ind Med (1983) 1.13
The active site regions of lacZ and ebg beta-galactosidases are homologous. J Biol Chem (1983) 1.13
In situ analysis of pH gradients in mosquito larvae using non-invasive, self-referencing, pH-sensitive microelectrodes. J Exp Biol (2001) 1.13
Double J stents. A review of 100 patients. Br J Urol (1986) 1.13
Gas treatment in trickle-bed biofilters: biomass, how much is enough? Biotechnol Bioeng (1997) 1.12